Antiandrogens: all 479 studies that test it
Page 4 of 5. Open to participants first (92), then studies with results posted, then the rest; newest registration first within each.
- A Study Evaluating HC-1119 Single-Dose Pharmacokinetics and Effect of Food on Its PharmacokineticsCompletedNCT03776968Phase 1
- A Study Evaluating Tolerability, Pharmacokinetics, and Preliminary Efficacy of HC-1119 in Patients.CompletedNCT03774056Phase 1
- A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical ProstatectomyActive, not recruitingNCT03767244Phase 3
- Neoadjuvant Pembrolizumab Plus Androgen Axis Blockade Prior to Prostatectomy for High Risk Localized Prostate CancerStatus unknownNCT03753243Phase 2
- Enzalutamide With Venetoclax in Treating Patients With Metastatic Castration Resistant Prostate CancerCompletedNCT03751436Phase 1
- Enzalutamide and Decitabine in Treating Patients With Metastatic Castration Resistant Prostate CancerWithdrawnNCT03709550Phase 1/2
- Imaging Study to Compare Effects of Darolutamide and Enzalutamide With Respect to Placebo on the Blood Flow in the Brain in Healthy Male Volunteers.CompletedNCT03704519Phase 1
- Biomarker Analysis of Castration-resistant Prostate Cancer Undergoing Treatment With Docetaxel Followed by EnzalutamideActive, not recruitingNCT03700099Phase 2
- Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer PatientsActive, not recruitingNCT03650894Phase 2
- A Pilot Study of Hormonal Therapy Combined With Central Memory T Cells (Tcm) for Patients With Advanced Prostate CancerStatus unknownNCT03587285Phase 1/2
- A Study of Androgen Receptor (AR) Antagonist Apalutamide in Chinese Participants With Metastatic Castration-Resistant Prostate CancerActive, not recruitingNCT03523442Phase 1
- Apalutamide With Radiotherapy and Androgen Deprivation Therapy in Prostate CancerWithdrawnNCT03488810Phase 3
- Enzalutamide in Metastatic or Advanced Non-resectable Granulosa Cell Ovarian Tumors: GREKO III StudyCompletedNCT03464201Phase 2
- Prostate Cancer Biomarker Enrichment and Treatment SelectionActive, not recruitingNCT03385655Phase 2
- Study on Androgen Receptor and Triple Negative Breast CancerCompletedNCT03383679Phase 2
- Therapeutics in Active Prostate Cancer SurveillanceCompletedNCT03365297Phase 2
- Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants With Metastatic Castration Resistant Prostate CancerTerminatedNCT03360721Phase 2
- A Study to Evaluate the Safety, Tolerability and Efficacy of a Liproca® Depot Injection in Patients With Prostate CancerCompletedNCT03348527Phase 2
- Enzalutamide With or Without Radium Ra 223 Dichloride in Patients With Metastatic, Castration-Resistant Prostate CancerActive, not recruitingNCT03344211Phase 2
- A Study of Patient Preference Between ODM-201 and Enzalutamide in Men With Metastatic Castrate-resistant Prostate CancerCompletedNCT03314324Phase 2
- Dynamics of Androgen Receptor Genomics and Transcriptomics After Neoadjuvant Androgen AblationCompletedNCT03297385Phase 2
- Optimal Sequencing of Treatment Options for Poor Risk mCRPC Previously Treated With DocetaxelCompletedNCT03295565Phase 2/3
- Drug-drug-interaction Study to Assess the Effect of Darolutamide on the Pharmacokinetics of Probe Substrates of CYP3A4 and P-gp in Healthy Male VolunteersCompletedNCT03237416Phase 1
- Alpelisib and Enzalutamide in Treating Patients With Androgen Receptor and PTEN Positive Metastatic Breast CancerCompletedNCT03207529Phase 1
- Enzalutamide and External Beam Hypofractionated Radiotherapy For Intermediate Risk Localized Prostate CancerStatus unknownNCT03196388Phase 2
- Efficacy of Rotations Between Abiraterone Acetate and Apalutamide in mCRPC PatientsWithdrawnNCT03173859Phase 2
- Bicalutamide and Raloxifene Hydrochloride in Treating Patients With Prostate Cancer Undergoing SurgeryWithdrawnNCT03147196Phase 2
- Randomized Phase II Study of Salvage XRT + ADT +/- Abiraterone and Apalutamide for Rising PSA After RP (FORMULA-509)Status unknownNCT03141671Phase 2
- Effect of Enzalutamide Dose Reduction on Fatigue, Cognition, and Drug Trough Levels in Patients With Prostate CancerStatus unknownNCT03124615Phase 2
- Neoadjuvant Apalutamide (ARN509) and Radical Prostatectomy in Treatment of Intermediate to High Risk Prostate CancerCompletedNCT03124433Phase 2
- Enzalutamide and Niclosamide in Treating Patients With Recurrent or Metastatic Castration-Resistant Prostate CancerCompletedNCT03123978Phase 1
- Early Rising PSA Endocrine Treatment Versus Chemo-endocrine Therapy- SPCG14Status unknownNCT03119857Phase 3
- A Phase II Study Evaluating the Efficacy of Enzalutamide and the Role of ARv7 in Metastatic Castration Resistant Prostate Cancer (mCRPC) Patients With Visceral Disease.CompletedNCT03103724Phase 2
- Ribociclib and Bicalutamide in AR+ TNBCActive, not recruitingNCT03090165Phase 1/2
- Active Surveillance With or Without Apalutamide Treatment in Low Risk Prostate CancerCompletedNCT03088124Phase 2
- Neoadjuvant Degarelix With or Without Apalutamide (ARN-509) Followed by Radical ProstatectomyActive, not recruitingNCT03080116Phase 2
- Bicalutamide in Treatment of Androgen Receptor (AR) Positive Metastatic Triple Negative Breast CancerTerminatedNCT03055312Phase 3
- Drug-drug Interaction (DDI) Study to Assess ODM-201 as a Victim of CYP3A4 Inhibition or InductionCompletedNCT03048110Phase 1
- Functional Study of the Hypothalamus in Magnetic Resonance Imaging (MRI) in Polycystic Ovary Syndrome (PCOS)CompletedNCT03043924Not applicable
- Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate CancerActive, not recruitingNCT03016741Phase 4
- ODM-201 vs Androgen Deprivation Therapy in Hormone naïve Prostate CancerActive, not recruitingNCT02972060Phase 2
- A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical StudyActive, not recruitingNCT02960022Phase 2
- Androgen Receptor Antagonist ARN-509 With or Without Abiraterone Acetate, Gonadotropin-Releasing Hormone Analog, and Prednisone in Treating Patients With High-Risk Prostate Cancer Undergoing SurgeryActive, not recruitingNCT02949284Phase 2
- ODM-201 Maintenance Therapy in Patients With mCRPC Previously Treated With Novel Hormonal Agents.TerminatedNCT02933801Phase 2
- Efficacy and Safety Study of Enzalutamide in Combination With Paclitaxel Chemotherapy or as Monotherapy Versus Placebo With Paclitaxel in Patients With Advanced, Diagnostic-Positive, Triple-Negative Breast CancerWithdrawnNCT02929576Phase 3
- A Safety and Pharmacokinetics Study of Niraparib Plus an Androgen Receptor-Targeted Therapy in Men With Metastatic Castration-Resistant Prostate Cancer (BEDIVERE)CompletedNCT02924766Phase 1
- Phase I Trial of Apalutamide Plus Abiraterone Acetate, Docetaxel, and Prednisone in Patients With mCRPCCompletedNCT02913196Phase 1
- Bicalutamide Plus Aromatase Inhibitors in ER(+)/AR(+)/HER2(-) Metastatic Breast CancerStatus unknownNCT02910050Phase 2
- A Study of the Clinical Activity and Safety of JNJ-64041809, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Apalutamide Versus Apalutamide in Subjects With Metastatic Castration-resistant Prostate CancerWithdrawnNCT02906605Phase 2
- Effect of Hepatic and Renal Impairment on the Pharmacokinetics, Safety and Tolerability of BAY1841788 (ODM-201)CompletedNCT02894385Phase 1
- Enzalutamide Before Surgery in Treating Patients With Kidney CancerTerminatedNCT02885649Early Phase 1
- Study of Abiraterone Acetate Plus ADT Versus APALUTAMIDE Versus Abiraterone and APALUTAMIDE in Patients With Advanced Prostate Cancer With Non-castrate Testosterone LevelsCompletedNCT02867020Phase 2
- The Effects of OCP and Metformin on Clinical, Hormonal, Metabolic and Ultrasonographic Characteristics in PCOSCompletedNCT02866786Phase 4
- Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)Active, not recruitingNCT02861573Phase 1/2
- Pharmacokinetic Study of JNJ-56021927 When Taken Orally as Tablet Formulation in Healthy Male Japanese ParticipantsCompletedNCT02835508Phase 1
- Imaging Staging and Response Prediction in Metastatic Hormono-Sensitive Prostate Cancer Patients Receiving EnzalutamideCompletedNCT02815033Phase 2
- PET/CT and WB MRI for Staging and Response in CRPC Patients Receiving EnzalutamideCompletedNCT02814968Phase 2
- Apalutamide Plus Intermittent Hormone Therapy Versus Intermittent Hormone Therapy Alone in Prostate CancerWithdrawnNCT02811809Phase 2
- Feasibility Study of Adjuvant Enzalutamide for the Treatment of Early Stage AR (+) Triple Negative Breast CancerActive, not recruitingNCT02750358Phase 2
- Effects of Sex Steroids on the Serotonin SystemStatus unknownNCT02715232Phase 4
- Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate CancerActive, not recruitingNCT02703623Phase 2
- FDHT PET and Bicalutamide in Metastatic Breast CancerCompletedNCT02697032Phase 2
- Drug-drug Interaction Study Using Rosuvastatin as a Breast Cancer Resistant Protein (Efflux Transporter), Organic Anion-transporting Polypeptide (OATP)1B1, and OATP1B3 (Uptake Transporters) Probe SubstrateCompletedNCT02671097Phase 1
- Study of Enzalutamide With and Without Sorafenib in Advanced Hepatocellular Carcinoma PatientsCompletedNCT02642913Phase 1
- Palbociclib in Combination With Bicalutamide for the Treatment of AR(+) Metastatic Breast Cancer (MBC)Active, not recruitingNCT02605486Phase 1/2
- A Study to Evaluate the Effect of Multiple Doses of JNJ-56021927 on the Pharmacokinetics of Multiple Cytochrome P450 and Transporter Substrates in Participants With Castration-Resistant Prostate CancerActive, not recruitingNCT02592317Phase 1
- Japanese Research for Patients With Non-metastatic Castration Resistant Prostate Cancer - EnzalutamideCompletedNCT02588001Not applicable
- A JNJ-56021927 (ARN-509; Apalutamide) QT/QTc StudyCompletedNCT02578797Phase 1
- Niclosamide and Enzalutamide in Treating Patients With Castration-Resistant, Metastatic Prostate CancerCompletedNCT02532114Phase 1
- An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLASActive, not recruitingNCT02531516Phase 3
- A Study to Evaluate the Pharmacokinetics of JNJ-56021927 in Participants With Mild or Moderate Hepatic Impairment Compared With Participants With Normal Hepatic FunctionCompletedNCT02524717Phase 1
- Open Label Phase Two Study of Enzalutamide With Concurrent Administration of Radium Ra 223 Dichloride in Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Symptomatic Bone MetastasisCompletedNCT02507570Phase 2
- Addition of Enzalutamide to First Line Docetaxel for Castration Resistant Prostate CancerCompletedNCT02453009Phase 2
- Enzalutamide in Androgen Deprivation Therapy With Radiation Therapy for High Risk, Clinically Localised, Prostate CancerActive, not recruitingNCT02446444Phase 3
- Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate CancerActive, not recruitingNCT02446405Phase 3
- Biomarkers of Androgen Response and Resistance In Evolution During a Rising PSACompletedNCT02429193Phase 2
- Mass Balance, Pharmacokinetics, Biotransformation and Bioavailability Study of ODM-201 in Healthy Male SubjectsCompletedNCT02418650Phase 1
- Clinical Trial to Study Quality of Life in Prostate Cancer Patients by Randomizing Anti-androgen Versus Total Androgen Blockage Prior to Curative Intended Radiation TherapyCompletedNCT02382094Phase 3
- Phase 1 Dose Escalation Study of BAY 1841788 in Japanese Metastatic Castration-resistant Prostate Cancer (mCRPC) SubjectsCompletedNCT02363855Phase 1
- AR-inhibitor Bicalutamide in Treating Patients With TNBCStatus unknownNCT02353988Phase 2
- Bicalutamide as A Treatment in AR-positive Metastatic Triple-Negative Breast Cancer (mTNBC) PatientsTerminatedNCT02348281Phase 2
- Comparative Study of Alternative Antiandrogen (AA) Therapy and Early Initiating of Enzalutamide for Castration-resistant Prostate Cancer (CRPC) After Combined Androgen Blockade (CAB) Therapy.CompletedNCT02346578Phase 2
- High-Dose Brachytherapy in Treating Patients With Prostate CancerCompletedNCT02346253Not applicable
- A Study of 2-hydroxyflutamide (Liproca Depot), Injected Into the Prostate in Patients With Localized Prostate CancerCompletedNCT02341404Phase 2
- Enzalutamide and Metformin Hydrochloride in Treating Patients With Hormone-Resistant Prostate CancerCompletedNCT02339168Phase 1
- Analyze the Predictive Value of Gene TMPRSS2-ETS in Response to Enzalutamide in Patients With Prostate CancerCompletedNCT02288936Phase 2
- Study to Assess Drug-Drug Interaction Between Itraconazole or Gemfibrozil and JNJ-56021927CompletedNCT02230033Phase 1
- A Study to Evaluate How Daily Dosing With Enzalutamide Affects the Metabolism of Caffeine and Dextromethorphan in Men With Prostate CancerCompletedNCT02225093Phase 1
- Crizotinib in Combination With Enzalutamide in Metastatic Castration-resistant Prostate CancerCompletedNCT02207504Phase 1
- A Safety Study of JNJ-56021927 in Participants With Metastatic Castration-Resistant Prostate CancerCompletedNCT02162836Phase 1
- Bioavailability Study of 3 Tablet Formulations vs. Capsule Formulation of JNJ-56021927 in Fasting Healthy Male ParticipantsCompletedNCT02160756Phase 1
- A Phase II Neoadjuvant Study of Enzalutamide, Abiraterone Acetate, Dutasteride and Degarelix in Men With Localized Prostate Cancer Pre-prostatectomyWithdrawnNCT02159690Phase 2
- A Phase 2 Study of Bicalutamide Plus Finasteride in Men With MRI Detectable Prostate Nodules Undergoing Active SurveillanceWithdrawnNCT02146937Phase 2
- A Study to Evaluate How a Drug That Alters Liver Enzymes (Rifampin) Affects the Metabolism of Enzalutamide in MenCompletedNCT02138799Phase 1
- Enzalutamide in Combination With Gemcitabine and Nab-Paclitaxel for the Treatment of Advanced Pancreatic CancerCompletedNCT02138383Phase 1
- A Study to Investigate the Effect of Severely Diminished Liver Function on the Metabolism, Safety, and Tolerability of a Single Oral Dose of Enzalutamide in MenCompletedNCT02138162Phase 1
- Sequencing Abiraterone and Enzalutamide in mCRPCCompletedNCT02125357Phase 2
- Enzalutamide Plus Everolimus in Men With Metastatic Castrate-Resistant Prostate CancerCompletedNCT02125084Phase 1
- A Study to Monitor the Safety of Enzalutamide in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based ChemotherapyCompletedNCT02124668Phase 2
- A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate CancerActive, not recruitingNCT02123758Phase 1